曾新城
Newcity Tzeng
現 職：
Staff Scientist, Donald Danforth Plant Science Center
演講時間：
May 01,
11:05 am CDT, 短講
演講題目：
From Winning Nobel Prize to Precision Medicine: the Role of Biological Mass Spectrometry in the"Omics" World
講者介紹
今年年會我們非常榮幸能邀請到曾新城博士來分享「從諾貝爾獎到精準醫療：生物質譜法如何為生物分子體學開拓新疆域」
曾新城博士畢業於國立海洋大學食品科學系的學士與碩士學程，後又赴美取得奧瑞岡州立大學(Oregon State University)的分析化學博士。在聖路易華盛頓大學醫學院完成兩年的博士後研究後，於2016年加入了Donald Danforth Plant Science Center，目前在其質譜核心實驗室擔任研究員，負責主導蛋白質體學相關的研究項目。
新城在這次年會中將和我們分享甚麼是質譜(mass spectrometry)，以及質譜技術在生醫領域，尤其是生物分子體學領域的重要性。他還將藉由台灣日前發表的一項肺癌機轉研究在跨國癌症登月研究計畫(The Cancer Moonshot)中的貢獻，來分享整合不同的分子體學和臨床數據的重要性。
隨著我們走向個人化醫療的時代，了解其發展的脈絡，有助我們預知未來的走向。趕快報名一起來享受這場生物醫學的盛宴吧!
講者經歷
Shin-Cheng (aka. Newcity) currently is the proteomics staff scientist in the Mass Spectrometry Facility at the Donald Danforth Plant Science Center. His role as the proteomics lead person in the facility oversaw the direction and execution of all protein-related project activities with internal and external laboratories and entities. Shin-Cheng studied biological mass spectrometry in graduate school and received his Ph.D. in Chemistry from Oregon State University. Prior to joining the Danforth center, Shin-Cheng did his postdoctoral training in Washington University, School of Medicine, where he participated researches in deciphering mechanism of novel cancer treatment and assessment of new data acquisition methodology using mass spectrometry. During his 10+ years of graduate and post-graduate research, Shin-Cheng has published several papers in prestigious journals such as Science, Cell report and Nature Communication, across varieties of topics like plant pathology, cancer biology and new method development applying mass spectrometry and chemical tagging. Shin-Cheng is enjoying working with researchers from various disciplines to solve challenges in biological science with innovative strategies combining, but not restricted to, chemistry, chromatography and mass spectrometry.
摘要
As we moved toward the era of precision medicine, we have heard a lot about big data and all kinds of "Omics". Two pillars of the Omics: Proteomics and Metabolomics are driven by the advancement of mass spectrometry. In this talk, first we will talk about what the mass spectrometry is and what it can do. Then, after 20 years in the making, where we are now in those fields and what the challenges are. We will discuss about a recent lung cancer research in Taiwan that was part of a multinational cancer moonshot research initiative as an example of successful integration of different Omics and clinical data. As the technology and science keep advancing and maturing, the era of precision medicine is approaching.